What Happens to First Trimester Nuchal Translucency

What Happens to First Trimester Nuchal Translucency Greater Than or Equal 99ème Percentile and Inferior 3.5 mm

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04541966

Enrollment

230

Registered

2020-09-09

Start date

2020-05-01

Completion date

2020-09-01

Last updated

2020-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nuchal Translucency

Keywords

Ultrasound abnormalities, Genetic abnormalities

Brief summary

First trimester nuchal translucency is a call point for genetic abnormalities and birth defects. Nuchal translucency varies with LCC and therefore with gestational age as described by Chung et al who created a 99th percentile curve of nuchal translucency versus LCC. The majority of centers use the 3.5 mm cutoff as the 99th percentile instead of using nuchal translucency based on LCC. The objective of this study is to compare the fate of nuchal hyperclites\> = 99th p but \<3.5mm versus 3.5mm. For this the investigators have studied the ultrasound and genetic abnormalities. The investigators were also interested in the pregnancy outcomes and the percentage of pregnancies in the group\> = 99th p and \<3.5mm that would have been sampled for a high combined risk for trisomy 21, and therefore to determine the benefit of a systematic sample. for HCN as well as the interest of performing an ACPA that would not be performed on a sample with a high risk of trisomy 21.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

nuchal translucency\> = 99th percentile

Exclusion criteria

\- multiple pregnancies

Design outcomes

Primary

Measure	Time frame	Description
Pregnancies without ultrasound or genetic abnormalities	immediate antenatal and postnatal period	Pregnancies without ultrasound or genetic abnormalities

Secondary

Measure	Time frame	Description
ACPA interest	immediate antenatal and postnatal period	ACPA interest
percentage of samples for high risk combined for trisomy 21	immediate antenatal and postnatal period	percentage of samples for high risk combined for trisomy 21
Pregnancy outcomes	immediate antenatal and postnatal period	Pregnancy outcomes

Countries

France

Outcome results